Organ Transplant Immunosuppressant Drugs Global Market Report 2024

The organ transplant immunosuppressant drugs market has grown steadily in recent years. It will grow from $5.24 billion in 2023 to $5.42 billion in 2024 at a compound annual growth rate (CAGR) of 3.4%. In the historic period, growth can be credited to various contributing factors. There was a notable increase in transplant procedures, bolstered by advancements in healthcare infrastructure and substantial investments in research and development. The global aging population also played a significant role, alongside heightened awareness regarding the importance and viability of organ transplantation.

The organ transplant immunosuppressant drugs market is expected to see steady growth in the next few years. It will grow to $6.29 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. Anticipated growth in the forecast period is expected to result from several key factors. These include the emergence of novel therapies, a noticeable upsurge in organ failure incidences, the advent of personalized medicine, and the influence of global health initiatives, supported by international collaborations.

The organ transplant immunosuppressant drugs market is poised for growth due to the increasing demand for organ transplantation. This life-saving surgical procedure involves replacing damaged organs with healthy ones from donors. Immunosuppressant drugs are vital to prevent organ rejection post-transplantation. Notably, in 2021, the Global Observatory on Donation and Transplantation reported a significant 11.3% annual increase, with 144,302 organ transplants performed. This surge underscores the driving force propelling the organ transplant immunosuppressant drugs market.

The expanding geriatric population is projected to fuel the growth of the organ transplant immunosuppressant drugs market. Immunosuppressants are crucial for elderly transplant recipients, necessitating tailored drug regimens to prevent rejection while mitigating potential adverse effects and drug interactions. By 2030, the World Health Organization estimates that 1 in 6 people worldwide will be aged 60 or older, reaching 1.4 billion, doubling to 2.1 billion by 2050. This demographic shift underscores the market's growth driven by the expanding geriatric populace.

Product innovation emerges as a key trend shaping the organ transplant immunosuppressant drugs market. Major industry players are focused on developing innovative solutions such as combination therapies, enhancing immunosuppression efficacy while reducing side effects. For example, in July 2021, the FDA approved Prograf for use in combination with other immunosuppressants, expanding its application to prevent organ rejection in kidney, liver, or heart transplant recipients. This emphasis on combination therapies aligns with market demand for improved treatment options.

Market leaders in the organ transplant immunosuppressant drugs sector prioritize advanced drug solutions to augment their product portfolios and meet patient needs. Advanced medications aim to modulate the immune system in transplant recipients. For instance, in August 2023, Strides Pharma Science Ltd. secured USFDA approval for Cyclosporine Softgel Capsules USP (Modified), catering to kidney, liver, and heart transplant recipients. This approval reinforces Strides' position in the immunosuppressant market, complementing their existing offerings and enhancing patient care outcomes.

In September 2021, Sanofi S.A., a leading French pharmaceutical and healthcare enterprise, successfully acquired Kadmon Holdings for around $1.9 billion. This strategic move by Sanofi was driven by its goal to amplify its transplant-related portfolio and pipeline. The acquisition primarily aimed to incorporate Kadmon's immunosuppressant drug, Rezurock, recently approved by the US FDA for addressing chronic graft-versus-host disease (cGVHD). Kadmon Holdings Inc., a US-based biopharmaceutical company, specializes in the development and distribution of organ transplant immunosuppressant drugs.

Major companies operating in the organ transplant immunosuppressant drugs market report are Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, GlaxoSmithKline PLC, Pfizer Inc., Sanofi S.A., Alsachim a Shimadzu Group Company, Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Asahi Kasei Corporation, Bristol-Myers Squibb Company, GSK PLC, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Hansa Biopharma AB, Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Biocon Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited.

North America was the largest region in the organ transplant immunosuppressant drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global organ transplant immunosuppressant drugs market report during the forecast period. The regions covered in the organ transplant immunosuppressant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the organ transplant immunosuppressant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

These drugs primarily fall into several classes calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and other miscellaneous classes. Calcineurin, an enzyme pivotal in T-cell activation, prompts the immune system to attack transplanted organs. Calcineurin inhibitors serve to prevent such rejection reactions in patients undergoing organ transplantation. These drugs find extensive use in heart, kidney, liver, lung, pancreas, and other organ transplants, and they are typically dispensed through hospital pharmacies, retail outlets, and online pharmacy platforms.

The organ transplant immunosuppressant drugs market research report provides organ transplant immunosuppressant drugs market statistics, including organ transplant immunosuppressant drugs industry global market size, regional shares, competitors with an organ transplant immunosuppressant drugs market share, detailed organ transplant immunosuppressant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the organ transplant immunosuppressant drugs industry. This organ transplant immunosuppressant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The organ transplant immunosuppressant drugs market consists of sales of drugs such asteroid-sparing immunosuppressants, prednisone, antineoplastics, monoclonal antibody drug, and immunosuppressive agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.